 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

This is a signal that ALT's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Altimmune (ALT, $3.06) RSI Indicator left the overbought zone on November 27, 2023

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Altimmune (ALT Research Report) and SurModics (SRD...

Analysts Offer Insights on Healthcare Companies: Altimmune (ALT) and SurModics (SRDX)

Top-line 48-week results from the MOMENTUM Phase 2 obesity trial expected Q4 2023 Pemvidutide granted Fast Track designation for the treatment of non-alcoholic steatohepatitis (NASH) Top-line...

Altimmune Announces Third Quarter 2023 Financial Results and Provides a Business Update

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Seagen (SGEN Research Report) and Altimmune (ALT...

Analysts Offer Insights on Healthcare Companies: Seagen (SGEN) and Altimmune (ALT)

GAITHERSBURG, Md., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2023 financial...

Altimmune to Report Third Quarter 2023 Financial Results and Provide Business Update on November 7, 2023

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Altimmune granted Fast Track designation by FDA for pemvidutide

GAITHERSBURG, Md., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has...

Altimmune Granted Fast Track Designation by FDA for Pemvidutide for the Treatment of Non-Alcoholic Steatohepatitis (NASH)

GAITHERSBURG, Md., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that new data on the anti-inflammatory and...

Altimmune to Present New Data on the Anti-Inflammatory and Anti-Fibrotic Properties of Pemvidutide in a Late-Breaking Presentation at The Liver Meeting  2023

Allspring Global Investments Holdings LLC acquired a new position in shares of Altimmune, Inc. (NASDAQ:ALT  Free Report) in the second quarter, according to the company in its most recent...

19,842 Shares in Altimmune, Inc. (NASDAQ:ALT) Acquired by Allspring Global Investments Holdings LLC

GAITHERSBURG, Md., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will...

Altimmune to Participate at Two Upcoming Investor Conferences

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Watchers	24,931
52-Wk Low	$2.09
52-Wk High	$17.17

Market Cap	$167.1M
Volume (M)	1.65M
52-Wk High	$17.17
52-Wk Low	$2.09

Period	Estimated	Reported	Surprise	Result
Q3'23	$-0.45	$-0.39	13.81%	BEAT
Q2'23	$-0.47	$-0.32	31.18%	BEAT
Q1'23	$-0.48	$-0.40	16.67%	BEAT
Q4'22	$-0.50	$-0.43	14.25%	BEAT
Q3'22	$-0.51	$-0.48	4.95%	BEAT

ALT Altimmune Inc

About

Feed

News

Sentiment

Earnings

Fundamentals